Galectin Therapeutics Inc.
corporate_fare Company Profile
Galectin Therapeutics Inc. (NASDAQ:GALT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for GALT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for GALT spans 10-Q, DEF 14A, PRE 14A, 8-K.
Recent high-impact activity:
- Galectin Narrows Q3 Loss to $3.6M as Phase 3 Protocol Sits With FDA
- Galectin 10-Q: Going Concern Warning, Cash Funds Operations Only Through June 2027
- Galectin Therapeutics Seeks Shareholder Approval to Double Authorized Shares to 250M
- Galectin Seeks Shareholder Nod to Nearly Double Authorized Shares to 250M
- Galectin Posts Wider Q2 Loss but Advances Belapectin Toward Phase 3
Financial Snapshot
Short Interest & Short Volume
46.26 days to coverFINRA reported short interest of 8,975,877 shares in GALT as of the October 30, 2026 settlement, a 1.7% decrease from the prior period — about 46.3 days to cover at its recent average daily volume. On November 20, 2026, 57.7% of GALT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for GALT, detected from its recent SEC filings · based on capital-structure filings through 2026-08-04.
Debt-to-Equity Conversion · Balance Sheet Transformation
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →